top of page
Double IHC2.png
OCMF Logo.png

2026 Featured Speakers

OCMF is honored to be featuring speakers from across a number of institutions and disciplines. 

Matulonis.jpg

Keynote

Ursula Matulonis, MD

Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.

​​

Topic: Targeting genomic vulnerabilities to improve ovarian cancer therapeutics

Conejo-Garcia.jfif

Keynote

Jose Conejo-Garcia, MD, PhD

 Chair of the Department of Immunology at H. Lee Moffitt Cancer Research Institute and Professor of Immunology at Duke University School of Medicine. 

​

Topic: Closing in: Cracking Ovarian Cancer's Resistance to Immunotherapy

Kate Chiappinelli, PhD

Targeting transposable elements to reverse ovarian cancer immune evasion

George Washington University

​​

Fergus Couch, PhD

Precise risk estimation for inherited variants in cancer predisposition genes

Mayo Clinic

​​​

Stephanie Gaillard, MD, PhD

Harnessing Therapeutic Vulnerabilities in ARID1A mutated ovarian cancers

Johns Hopkins

​

Gordon Mills, MD, PhD

Improving the failure rate of Ovarian Cancer Clinical Trials

Oregon Health and Science University 

​​

Matthew Powell, MD

New targeted treatments to improve outcomes for women with endometrial cancers: recent clinical advances.

Washington University School of Medicine​​​​​​

​

Kathryn R. Taylor, PhD

The neural regulation of pediatric cancer

Memorial Sloan Kettering Cancer Center

​

​

Jeremy Chien, PhD

Genetic, epigenetic, and functional characterization of DTP cells in vitro and in situ in ovarian cancer

University of California - Davis

​

Analisa DiFeo, PhD

Unraveling Innovative Therapies through Tumor Analysis and Genetic Insights

University of Michigan School of Medicine ​
 

David Mutch, MD

Pearls and pitfalls of submitting a SPORE grant

Washington University School of Medicine

​​

Amy Skubitz, PhD 

Identification of ovarian cancer protein biomarkers in Pap tests 

University of Minnesota

​​

Jordyn Silverstein, MD

Claudin-6 as a novel therapeutic target in ovarian cancer

UCLA

​

Ashani Weeraratna, PhD

A Complex TiME: How aging drives tumor progression

Johns Hopkins

​

Andrea Wahner Hendrickson, MD

Clinical Trials in Ovarian Cancer

Mayo Clinic

bottom of page